Publisher
Japanese Society on Thrombosis and Hemostasis
Reference7 articles.
1. 1) Lui CY, Wallen P, Handley DA: Fibrinogen New York I: Mechanism for defective fibrin potentiation of plasminogen activator by tissue-plasminogen activator. Thromb Haemost 54: 108 (Abst), 1985.
2. 2) Carrell N, Gabriel DA, Blatt PM, et al.: Hereditary dysfibrinogenemia in patient with thrombotic disease. Blood 62: 439–447, 1983.
3. 3) Engesser L, Koopman J, Munk de G, et al.: Fibrinogen Nijmegen: Congenital dysfibrinogenemia associated with impaired t-PA mediated plasminogen activation and decreased binding of t-PA. Thromb Haemost 60: 113–120, 1988.
4. 4) Ieko M, Sawada K-I, Sakurama S, et al.: Fibrinogen Date: Congenital hypodysfibrionogenemia associated with decreased binding of tissue-plasminogen activator. Am J Hematol 37: 228–233, 1991.
5. 5) Ieko M, Ichikawa K, Triplett DA, et al.: β2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies. Arthritis Rhrum 42: 167–174, 1999.